Abstract
Introduction: Ultrasound biomicroscopy (UBM) is the only widely used method for the evaluation of anterior uveal melanoma (AUM). Objective: Documentation of regression of AUM treated with ruthenium-106 (Ru-106) plaque types CCB and CCC using UBM. Methods: This single institution-based retrospective case series involved 10 Caucasian patients with AUM followed after brachytherapy with UBM from January 2014 until February 2019. The largest prominence of the tumor perpendicular to the sclera or the cornea (including scleral/corneal thickness) (D) and the largest basal dimension (B) were measured in millimeters with UBM for all patients prior to the brachytherapy and at 4-month interval follow-up. Tumor regression was calculated as a percentage of decrease in the initial D and B values. Results: The study involved 10 patients with a mean age of 64.4 years (yr) (range 46–80 yr). D ranged from 1.82 to 5.5 mm (median 2.99 mm) and B from 2.32 to 12.38 mm (median 4.18 mm). The apical radiation dose in all patients was 100 Gy. The median follow-up was 42.02 months. Regression for D was 21.11 ± 13.66%, 31.09 ± 14.66%, and 34.92 ± 19.86% at 1st, 2nd, and 3rd year of the follow-up, respectively, while for B it was 21.58 ± 16.05%, 28.98 ± 17.71%, and 32.06 ± 18.96%, respectively. Tumor recurrence was documented in 2/10 patients. Conclusion: The major regression of AUM, treated with Ru-106 plaque types CCB and CCC, was documented in the first 2 years after brachytherapy in our study group. In the following years, only minimal regression was documented that warns of the need for close monitoring and active search for local recurrences.
References
1.
Simpson
ER
, Gallie
B
, Laperrierre
N
, Beiki-Ardakani
A
, Kivelä
T
, Raivio
V
, et al. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma
. Brachytherapy
. 2014
;13
(1
):1
–14
. .2.
Razzaq
L
, Keunen
JE
, Schalij-Delfos
NE
, Creutzberg
CL
, Ketelaars
M
, De Keizer
RJ
. Ruthenium plaque radiation therapy for iris and iridociliary melanomas
. Acta Ophthalmol
. 2012 May
;90
(3
):291
–6
. .3.
Kuzmanović Elabjer
B
, Bušić
M
, Miletić
D
, Bjeloš
M
, Vukojević
N
, Bosnar
D
. Scleral thinning documented by ultrasound biomicroscopy after plaque therapy for anterior ciliary melanoma
. Semin Ophthalmol
. 2018 May
;33
(4
):571
–5
. .4.
Rospond-Kubiak
I
, Wróblewska-Zierhoffer
M
, Twardosz-Pawlik
H
, Kocięcki
J
. Ruthenium brachytherapy for uveal melanoma: single institution experience
. J Contemp Brachytherapy
. 2017
;9
(6
):548
–52
. .5.
Hyrcza
M
. Uvea: pathologic TNM staging of uveal melanoma, AJCC 8th edition [Internet]
. PatahologyOutlines.com website. [cited 2020 May 11]. Available from: http://www.pathologyoutlines.com/topic/eyeuveatnmuvealmelanoma.html
.6.
Kaiserman
I
, Anteby
I
, Chowers
I
, Blumenthal
EZ
, Kliers
I
, Pe’er
J
. Changes in ultrasound findings in posterior uveal melanoma after ruthenium 106 brachytherapy
. Ophthalmology
. 2002 Jun
;109
(6
):1137
–41
. .7.
Abramson
DH
, Servodidio
CA
, McCormick
B
, Fass
D
, Zang
E
. Changes in height of choroidal melanomas after plaque therapy
. Br J Ophthalmol
. 1990 Jun
;74
(6
):359
–62
. .8.
Weis
E
, Salopek
TG
, McKinnon
JG
, Larocque
MP
, Temple-Oberle
C
, Cheng
T
, et al. Management of uveal melanoma: a consensus-based provincial clinical practice guideline
. Curr Oncol
. 2016
;23
(1
):e57
–64
. .9.
Shields
CL
, Kaliki
S
, Furuta
M
, Mashayekhi
A
, Shields
JA
. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases
. Retina
. 2012 Jul
;32
(7
):1363
–72
. .10.
Costache
M
, Patrascu
OM
, Adrian
D
, Costache
D
, Sajin
M
, Ungureanu
E
, et al. Ciliary body melanoma: a particularly rare type of ocular tumor. Case report and general considerations
. Maedica
. 2013 Sep
;8
(4
):360
–4
.11.
Marigo
FA
, Finger
PT
. Anterior segment tumors: current concepts and innovations
. Surv Ophthalmol
. 2003
;48
(6
):569
–93
. .12.
Brewington
BY
, Shao
YF
, Davidorf
FH
, Cebulla
CM
. Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions
. Clin Ophthalmol
. 2018 May
;12
:925
–34
. .13.
Naseripour
M
, Jaberi
R
, Sedaghat
A
, Azma
Z
, Nojomi
M
, Falavarjani
KG
, et al. Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate
. J Contemp Brachytherapy
. 2016
;8
(1
):66
–73
. .14.
Eckert & Ziegler BEBIG
. Ru-106 eye applicators and I-125 ophthalmic seeds [Internet]
. Eckert & Ziegler BEBIG. [cited 2020 May 11]. Available from: https://www.bebig.com/fileadmin/bebig_neu/user_uploads/Products/Ophthalmic_Brachytherapy/Ophthalmic_Brochure__Rev._06__English.pdf
.15.
Eckert & Ziegler BEBIG
. Ru-106 eye applicators [Internet]
. Eckert & Ziegler BEBIG. [cited 2020 May 11]. Available from: https://www.bebig.com/fileadmin/bebig_neu/user_uploads/Products/Ophthalmic_Brachytherapy/Fact_sheet_Ru-106_Eye_Applicators__Rev.06__English.pdf
.16.
Rashid
M
, Heikkonen
J
, Kivelä
T
. Tumor regression after brachytherapy for choroidal melanoma: reduction of thickness and cross-sectional area by shape and regression pattern
. Invest Ophthalmol Vis Sci
. 2015 Apr
;56
(4
):2612
–23
. .17.
Novak-Andrejčič
K
, Jančar
B
, Hawlina
M
. Echographic follow-up of malignant melanoma of the choroid after brachytherapy with 106Ru
. Klin Monbl Augenheilkd
. 2003
;220
(12
):853
–60
.18.
James
K
, Eisenhauer
E
, Christian
M
, Terenziani
M
, Vena
D
, Muldal
A
, et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement
. J Natl Cancer Inst
. 1999
;91
(6
):523
–8
. .19.
Therasse
P
, Arbuck
SG
, Eisenhauer
EA
, Wanders
J
, Kaplan
RS
, Rubinstein
L
, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
. J Natl Cancer Inst
. 2000
;92
(3
):205
–16
. .20.
Barker
CA
, Francis
JH
, Cohen
GN
, Marr
BP
, Wolden
SL
, McCormick
B
, et al. 106Ru plaque brachytherapy for uveal melanoma: factors associated with local tumor recurrence
. Brachytherapy
. 2014 Nov
;13
(6
):584
–90
.21.
Rouberol
F
, Roy
P
, Kodjikian
L
, Gérard
JP
, Jean-Louis
B
, Grange
JD
. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years’ experience with beta-rays)
. Am J Ophthalmol
. 2004 May
;137
(5
):893
–900
.22.
Kuzmanović Elabjer
B
, Bušić
M
, Bjeloš
M
, Miletić
D
, Vukojević
N
. A non-contiguous recurrence of the ciliary body melanoma-is cataract surgery a risk factor?
Int J Ophthalmol
. 2020 Apr
;13
(4
):681
–3
. .23.
Damato
B
, Patel
I
, Campbell
IR
, Mayles
HM
, Errington
RD
. Local tumor control after 106Ru brachytherapy of choroidal melanoma
. Int J Radiat Oncol Biol Phys
. 2005 Oct
;63
(2
):385
–91
. .24.
Margo
CE
. The collaborative ocular melanoma study: an overview
. Cancer Control
. 2004 Sep-Oct
;11
(5
):304
–9
. .25.
Honavar
SG
. Is Collaborative Ocular Melanoma Study (COMS) still relevant?
Indian J Ophthalmol
. 2018 Oct
;66
(10
):1385
. .26.
Salvi
SM
, Aziz
HA
, Dar
S
, Singh
N
, Hayden-Loreck
B
, Singh
AD
. Uveal melanoma regression after Brachytherapy: relationship with chromosome 3 monosomy status
. Ocul Oncol Pathol
. 2017 Jul
;3
(2
):87
–94
. .27.
Urbak
SF
, Pedersen
JK
, Thorsen
TT
. Ultrasound biomicroscopy. II. Intraobserver and interobserver reproducibility of measurements
. Acta Ophthalmol Scand
. 1998
;76
(5
):546
–9
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
